Traws Pharma, Inc. Price & Performance (TRAW)

Traws Pharma's stock reached a 52-week low at $1.51, marking a 92% drop from its peak as the company navigates a leadership transition. Despite the decline, analysts maintain a "Strong Buy" outlook with a $6 target. Recent moves include a $50 million at-the-market offering and new CEO appointment, signaling ongoing strategic realignment.12

Onconova Therapeutics has seen its shares plunge over 90% year-over-year, yet analysts continue to set optimistic targets, with the average one-year price target at $8.50. The company maintains a healthy cash position and low debt, suggesting potential for recovery if its pipeline delivers on expectations.23

A recent analysis from MD Anderson Cancer Center shows patients with high-risk MDS or CMML treated with oral decitabine cedazuridine and venetoclax had improved one-year event-free survival compared to decitabine alone. The combination therapy also demonstrated lower relapse rates, offering encouraging data for future treatment protocols.45